| Jul 16 |
ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen® Will Debut at Leading Wellness Clinics in August
|
| Jul 12 |
When Will ChromaDex Corporation (NASDAQ:CDXC) Turn A Profit?
|
| Jul 1 |
ChromaDex to join Russell 2000 Index
|
| Jul 1 |
ChromaDex to Join Russell 2000® Index
|
| Jun 26 |
ChromaDex: Looking To Take The Big Step Into Pharma
|
| Jun 24 |
Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD)
|
| Jun 15 |
Here's Why We Think ChromaDex Corporation's (NASDAQ:CDXC) CEO Compensation Looks Fair
|
| Jun 13 |
ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC)
|
| Jun 10 |
ChromaDex (CDXC) Up as Ataxia Candidate Gets Orphan Drug Tag
|
| Jun 7 |
ChromaDex shares jump 9% on FDA designations for NRC
|
